HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exuviance Before/After Photos Overexpose Results – NAD

This article was originally published in The Rose Sheet

Executive Summary

NeoStrata will modify a print ad for its Exuviance anti-aging skin care products after NAD finds that “before” and “after” photos imply a claim about efficacy not supported by a study for one, though similar images are supported by a study on the efficacy of the second.

You may also be interested in...

Guthy-Renker Stands Firm Against NAD Finding On Crepe Erase Wrinkle Claim

Guthy-Renker disagrees with NAD's position the firm does not have objective evidence to support its treatment can “reverse crepey-looking skin.” NAD attorneys say the nature and extent of claims "should be directly analogous to the precision and specificity of the data used to substantiate.”

Cosmetic News In Brief: Revlon NAD Case; Farouk/LG Joint Venture; More

Following a National Advertising Division challenge from Coty, Revlon discontinues its express and implied claims for Colorstay, though maintains that the change was not a result of the challenge. CHI and BioSilk marketer Farouk Systems is teaming up with LG Household & Health Care to bring its products to the Asian market. More.

Too Nice 'N Easy? ASA Cites Timeline Issues In Clairol Ad Review

The real-world hair-coloring sequence did not exactly line up with that depicted in a Clairol Nice 'N Easy commercial featuring actress Christina Hendricks, the Advertising Standards Authority notes in a recent ruling. Due to that inconsistency and what ASA deems unsubstantiated "visual claims," the ad should be shelved, it says.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts